about
Cholangiocarcinoma: increasing burden of classificationsSensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell CulturesGABA induces the differentiation of small into large cholangiocytes by activation of Ca(2+) /CaMK I-dependent adenylyl cyclase 8.Concise review: clinical programs of stem cell therapies for liver and pancreasCharacterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling.After damage of large bile ducts by gamma-aminobutyric acid, small ducts replenish the biliary tree by amplification of calcium-dependent signaling and de novo acquisition of large cholangiocyte phenotypes.Role of follicle-stimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease.Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats.Polycystic liver diseases.Recent advances on the mechanisms regulating cholangiocyte proliferation and the significance of the neuroendocrine regulation of cholangiocyte pathophysiology.Transplantation of human fetal biliary tree stem/progenitor cells into two patients with advanced liver cirrhosis.Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.Role of sex hormones in the modulation of cholangiocyte function.Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor.Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease.Profiles of cancer stem cell subpopulations in cholangiocarcinomas.Adult Human Biliary Tree Stem Cells Differentiate to β-Pancreatic Islet Cells by Treatment with a Recombinant Human Pdx1 Peptide.Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cellsIschemia reperfusion of the hepatic artery induces the functional damage of large bile ducts by changes in the expression of angiogenic factors.Activation of alpha(1) -adrenergic receptors stimulate the growth of small mouse cholangiocytes via calcium-dependent activation of nuclear factor of activated T cells 2 and specificity protein 1.Cholangiocytes and blood supply.Morphological and functional heterogeneity of the mouse intrahepatic biliary epitheliumTaurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression.Biliary tree stem cells, precursors to pancreatic committed progenitors: evidence for possible life-long pancreatic organogenesis.Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expressionRole of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks.New insights into liver stem cells.Expression of vascular endothelial growth factors and their receptors by hepatic progenitor cells in human liver diseases.Recent advances in the morphological and functional heterogeneity of the biliary epithelium[Morphological aspects of atherosclerosis lesion: past and present]Paediatric nonalcoholic fatty liver disease.The fetal liver as cell source for the regenerative medicine of liver and pancreasThe hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration.Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors.Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma.Redox regulation of the influenza hemagglutinin maturation process: a new cell-mediated strategy for anti-influenza therapy.H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo.Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages.Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C.
P50
Q26991678-0951F12E-F792-4C93-BD2E-72DFC0FF0D94Q28550991-DC669C72-243A-48CC-97CB-1719A7FA9F0BQ30542145-60062331-A1F8-49D8-B92C-363CDCC5DC83Q30555472-5B12C365-5D23-4373-B433-049F894102DDQ33514261-D94B4404-D574-4079-B5A9-48C7B475097EQ33745195-4F24B9F0-9FB1-47C4-B497-9DC6C50F19A0Q33783730-4215715D-D287-4DC6-93EC-7C1CE07E7C45Q33936280-B1B8C079-D51E-4D5A-B0B8-87E298889317Q33949172-D2AEDD9A-FC2C-4A89-B212-8904C8AB195BQ34358007-2C482AFE-018E-45A0-9B13-76F306AA7C44Q34707880-5D23E613-2377-4532-BFD5-F385A27E48ECQ34979300-EC801226-F9F0-4945-A3A9-2A6CC84B80FFQ34992322-FA0C9256-64A4-4A76-BF1A-D9CD650454D9Q35012302-0E8D0C5E-F575-4507-924E-1A792C99D28DQ35088371-A7F93A63-596D-4758-A685-0736A1D4C52AQ35669078-6CE407BB-FBAC-4567-98FE-943ABA20A73CQ35740094-E978739D-97EF-424F-A70A-3EB43BFB5FDDQ36145871-20FD4516-6667-4F48-B642-EEE875A7134CQ36345910-1A485F4C-CCEE-4593-9E74-26A1588F5D73Q36466409-B2996B28-0B97-426E-823B-74F3EB0208F7Q36506488-7583162C-6EE8-4D7D-98C6-AE7537A85DC4Q37142524-840CED4D-BAC1-45FF-8557-76E7B71B3AE7Q37157705-E4B5AA7B-577A-44BA-8771-9969703CCB9CQ37228093-38101B08-7484-43EF-8F7F-D8AEFB6F8CACQ37253350-57F32E30-B753-468B-A0F6-E43C16BCE31EQ37291238-A647FC15-67CB-46AB-9E12-A5A75ED6ADB1Q37464439-27E54F32-4DE7-42BB-849E-E96B3263E8E5Q37584658-1319C21B-D83B-4BE1-B91A-CC61F6FB9127Q37662251-DD8DFA08-13AB-4316-9221-6AEAB8521C6AQ37861924-6448848B-ED6F-4749-B546-2098A391A845Q38089514-7FCF051B-AF89-4608-8ECC-140B5C2640F5Q38261683-61ED74DD-88F2-4E8C-BD70-D30A1C3BCBBAQ38622477-B6AEC70D-14A8-43D2-AE74-BD92C0560BEAQ38682140-3BEC747D-1767-4928-B60A-91BF75B2B4AFQ39340369-13F6EEC2-BC44-455D-9A21-DBB86C6B62B2Q39583164-B85B9696-BDF8-4C3E-9BF2-61F3E81D16ACQ39787871-88EB5810-6224-458B-AB66-9D6D292A4487Q40962891-03312ECF-41DD-451B-9539-3B47DB868A57Q41979111-AFF5B70F-584E-4D40-9CA6-D995EED1ED80Q42978719-CC2EEE39-38DA-4E06-8BDB-1D9A0BCA138F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guido Carpino
@ast
Guido Carpino
@en
Guido Carpino
@es
Guido Carpino
@nl
type
label
Guido Carpino
@ast
Guido Carpino
@en
Guido Carpino
@es
Guido Carpino
@nl
prefLabel
Guido Carpino
@ast
Guido Carpino
@en
Guido Carpino
@es
Guido Carpino
@nl
P106
P1153
6508122425
P31
P496
0000-0001-8570-2519